DMARDs (biologic); disease activity; psoriatic arthritis
Methods: In ASTRAEA, patients with active PsA were randomised (1:1) to receive blinded weekly SC abatacept 125 mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients achieving American College of Rheumatology 20% improvement response, Disease Activity Score in 28 joints (DAS28 (C reactive protein (CRP))) ≤3.6 and
Results: Of 212/213 and 210/211 patients with baseline BMI data in the abatacept and placebo groups, respectively, 15% and 19% were underweight/normal, 36% and 27% were overweight, and 49% and 54% were obese. After adjusting for baseline characteristics, there were no significant differences for any outcome measure at week 24 with abatacept in the overweight or obese versus underweight/normal subgroup. In the placebo group, patients in the obese versus underweight/normal subgroup were significantly less likely to achieve DAS28 (CRP)
Conclusion: BMI does not impact clinical or radiographic response to SC abatacept in patients with PsA.
Trial registration number: NCT01860976.
Orthopedics & Sports Medicine
McInnes, Iain B; Ferraccioli, Gianfranco; D'Agostino, Maria-Antonietta; Le Bars, Manuela; Banerjee, Subhashis; Ahmad, Harris A; Elbez, Yedid; and Mease, Philip, "Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a" (2019). Articles, Abstracts, and Reports. 1705.